Bryan Therapeutics

Bryan Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare and orphan diseases with high unmet medical needs. The company's lead program, B-101, is a proprietary topical formulation of polyhexamethylene biguanide (PHMB) currently in Phase 3 clinical development for the treatment of Acanthamoeba keratitis, a severe and potentially blinding corneal infection. Bryan Therapeutics focuses on streamlining the regulatory path for orphan indications to bring life-changing treatments to patients quickly. Their strategy involves leveraging established compounds with known safety profiles in novel formulations and indications. The company is headquartered in Bedminster, New Jersey, and operates primarily within the ophthalmology and infectious disease sectors.